Loading
A phase 2 trial of Furmonertinib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting.
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion is a phase 2 interventional study registered as NCT05466149 by Allist Pharmaceuticals, Inc., with 100 participants enrolled, started 2022-09-27 and due to reach its primary completion in 2025-06-27. Interventions recorded: Furmonertinib.
Shares Shanghai Allist Pharmaceuticals, Furmonertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.